Lantern Pharma Inc. (NASDAQ: LTRN) announced that the European Medicines Agency has cleared an investigator-initiated Phase 1b/2 clinical trial of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA